Long-term effects of panax ginseng on disposition of fexofenadine in rats in vivo

American Journal of Chinese Medicine

Volumn 37, Issue 4, 2009, Pages 657-667

  Zhang, Ruhong ^a,b   Jie, Jinjie ^b   Zhou, Yan'an ^a   Cao, Zhijian ^a   Li, Wenxin ^a  

^a WUHAN UNIVERSITY   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Fexofenadine; P glycoprotein; Panax Ginseng

Indexed keywords

FEXOFENADINE; GINSENG EXTRACT; GLYCOPROTEIN P; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG CAPSULE; DRUG DISPOSITION; DRUG ELIMINATION; FEEDING; GINSENG; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; SUSPENSION;

ANIMALS; ANTI-ALLERGIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; MALE; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; PANAX; PLANT PREPARATIONS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TERFENADINE; TIME FACTORS;

EID: 69049101305     PISSN: 0192415X     EISSN: None     Source Type: Journal    
DOI: 10.1142/S0192415X09007144     Document Type: Article

References (33)

1. Attele, A.S., J.A. Wu and C.-S. Yuan. Ginseng pharmacology: Multiple constituents and multiple actions. Biochem. Pharmacol. 58: 1685-1693, 1999.
2. Balimane, P.V., K. Patel, A. Marino and S. Chong. Utility of 96 well Caco-2 cell system for increased throughput of P-gp screening in drug discovery. Eur. J. Pharm. Biopharm. 58: 99-105, 2004.
3. Becquemont, L., C. Verstuyft, R. Kerb, U. Brinkmann, M. Lebot, P. Jaillon and C. Funck-Brentano. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin. Pharmacol. Ther. 70: 311-316, 2001.
4. Caballero, E., I. Ocana, J.R. Azanza and B. Sadaba. Fexofenadine: A antihistaminic. Review of its practical characteristics. Rev. Med. Univ. Navarra 43: 93-97, 1999.
5. Carson, S.W., A.D. Ousmanou and S.L. Hoyler. Emerging significance of P-glycoprotein in understanding drug disposition and drug interactions in psychopharmacology. Psychopharmacol. Bull. 36: 67-81, 2002.
6. Cheng, T.O. Ginseng and other herbal medicines that interact with warfarin. Int. J. Cardiol. 104: 227, 2005a.
7. Cheng, T.O. Herbal interaction with warfarin. South Med. J. 98: 748, 2005b.
8. Cheng, T.O. Warfarin interaction with herbal drugs and food. Int. J. Cardiol. 119: 107-108, 2007.
9. Crivori, P., B. Reinach, D. Pezzetta and I. Poggesi. Computational models for identifying potential P-glycoprotein substrates and inhibitors. Mol. Pharm. 3: 33-44, 2006.
10. Cvetkovic, M., B. Leake, M.F. Fromm, G.R. Wilkinson and R.B. Kim. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab. Dispos. 27: 866-871, 1999.
11. Debri, K., A.R. Boobis, D.S. Davies and R.J. Edwards. Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissues. Biochem. Pharmacol. 50: 2047-2056, 1995.
12. Dresser, G.K., D.G. Bailey, B.F. Leake, U.I. Schwarz, P.A. Dawson, D.J. Freeman and R.B. Kim. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 71: 11-20, 2002.
13. Greiner, B.E.M., M. Eichelbaum, P. Fritz, H.-P. Kreichgauer, O. Von Richter, J. Zundler and H.K. Kroemer. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. [Erratum to document cited in CA131:179243]. J. Clin. Invest. 110: 571, 2002.
14. Ito, K.,H. Suzuki, T. Horie and Y. Sugiyama. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res. 22: 1559-1577, 2005.
15. Izzo, A.A., F. Borrelli and R. Capasso. Herbal medicine: The dangers of drug interaction. Trends Pharmacol. Sci. 23: 358-391; author reply 359, 2002.
16. Jiang, X., M.W. Kenneth, S.L. Winston, J.A. Alaina, D.R. Basil, C.D. Colin, O.D. Richard and J.M. Andrew. Effect of St. John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br. J. Clin. Pharmacol. 57: 592-599, 2004.
17. Jin, J., S. Shahi, H.K. Kang, H.W. van Veen and T.-P. Fan. Metabolites of ginsenosides as novel BCRP inhibitors. Biochem. Biophy. Res. Commun. 345: 1308-1314, 2006.
18. Jonker, J.W., G. Merino, S. Musters, A.E. van Herwaarden, E. Bolscher, E. Wagenaar, E. Mesman, T.C. Dale and A.H. Schinkel. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat. Med. 11: 127-129, 2005.
19. Kamath, A.V., M. Yao, Y. Zhang and S. Chong. Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J. Pharm. Sci. 94: 233-239, 2005.
20. Kharasch, E.D., C. Hoffer, D. Whittington and P. Sheffels. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin. Pharmacol. Ther. 74: 543-554, 2003.
21. Kim, S.-W., H.-Y. Kwon, D.-W. Chi, J.-H. Shim, J.-D. Park, Y.-H. Lee, S. Pyo and D.-K.Rhee. Reversal of P-glycoprotein-mediated multidrug resistance by ginsenoside Rg3. Biochem. Pharmacol. 65: 75-82, 2003.
22. Krishna, D.R. and U. Klotz. Extrahepatic metabolism of drugs in humans. Clin. Pharmacokinet. 26: 144-160, 1994.
23. Liu, K.H., M.J. Kim, B.H. Jeon, J.H. Shon, I.J. Cha, K.H. Cho, S.S. Lee and J.G. Shin. Inhibition of human cytochrome P450 isoforms and NADPH-CYP reductase in vitro by 15 herbal medicines, including Epimedii herba. J. Clin. Pharm. Ther. 31: 83-91, 2006.
24. Merino, G., A.J. Molina, J.L. Garcia, M.M. Pulido, J.G. Prieto and A.I. Alvarez. Ginseng increases intestinal elimination of albendazole sulfoxide in the rat. Comp. Biochem. Phys. C Toxicol. Pharmacol. 136: 9-15, 2003.
25. Miller, K.L., R.S. Liebowitz and L.K. Newby. Complementary and alternative medicine in cardiovascular disease: A review of biologically based approaches. Am. Heart J. 147: 401-411, 2004.
26. Odani, T.,H. Tanizawa andY. Takino. Studies on the absorption, distribution, excretion and metabolism of ginseng saponins. IV. Decomposition of ginsenoside-Rg1 and -Rb1 in the digestive tract of rats. Chem. Pharm. Bull. (Tokyo) 31: 3691-3697, 1983.
27. Pal, D. and A.K. Mitra. MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci. 78: 2131-2145, 2006.
28. Perloff, M.D., L.L. Von Moltke, E. Stormer, R.I. Shader and D.J. Greenblatt. Saint John's wort: An in vitro analysis of P-glycoprotein induction due to extended exposure. Br. J. Pharmacol. 134: 1601-1608, 2001.
29. Schuetz, E.G., K.N. Furuya and J.D. Schuetz. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J. Pharmacol. Exp. Ther. 275: 1011-1018, 1995.
30. Tahara, H., H. Kusuhara, E. Fuse and Y. Sugiyama. P-glycoprotein plays a major role in the efflux of fexofenadine in the small intestine and blood-brain barrier, but only a limited role in its biliary excretion. Drug Metab. Dispos. 33: 963-968, 2005.
31. Tong, Y., R. Zhang, S.N. Ngo and A.K. Davey. Alteration of fexofenadine disposition in the rat isolated perfused liver following injection of bacterial lipopolysaccharide. Clin. Exp. Pharmacol. Physiol. 33: 685-689, 2006.
32. Yuan, C.S., G. Wei, L. Dey, T. Karrison, L. Nahlik, S. Maleckar, K. Kasza, M. Ang-Lee and J. Moss. Brief communication - American ginseng reduces warfarin's effect in healthy patients: A randomized, controlled trial. Ann. Intern. Med. 141: 23-27, 2004.
33. Zhang, Y. and L.Z. Benet. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 40: 159-168, 2001.